DF/HCC SPORE in Prostate Cancer

描述（由申请人提供）：本申请代表达纳法伯哈佛癌症中心（DF/HCC）前列腺癌孢子的更新申请。该申请涉及来自哈佛大学几所机构的基础、转化和临床研究人员，包括贝斯以色列女执事医疗中心、波士顿儿童医院、布里格姆妇女医院、达纳法伯癌症研究所、哈佛大学公共卫生学院和马萨诸塞州总医院。布罗德研究所（Broad Institute）的研究人员也参与其中。布罗德研究所是由哈佛医学院（Harvard Medical School）和麻省理工学院（Massachusetts Institute of Technology）合作成立的基因组研究所。该项目将支持5个项目，包括：1)致死性和惰性前列腺癌的分子特征；2)8q24前列腺癌风险位点的遗传和临床特征；3)前列腺癌激酶抑制剂联合治疗的开发；4)通过化学基因组学调节转录因子靶点；5)激素难治性疾病的雄激素信号传导。这些项目将由三个核心支持：1)管理，评估和规划2)生物统计学和计算生物学3)组织和病理学。我们还包括发展项目和职业发展项目。DF/HCC SPORE的总体目标是将生物学和技术进步转化为前列腺癌男性患者的临床有意义的进步。

DESCRIPTION (provided by applicant): This application represents a renewal application of the Dana Farber Harvard Cancer Center (DF/HCC) Prostate Cancer SPORE. The application involves basic, translational and clinical investigators from several Harvard Institutions including the Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard School of Public Health and the Massachusetts General Hospital. It also involves investigators from the Broad Institute, a genomics institute formed through a collaboration between Harvard Medical School and the Massachusetts Institute of Technology. Five Projects will be supported in this application including 1) Molecular Signatures of Lethal and Indolent Prostate Cancer 2) Genetic and Clinical Characterization of the 8q24 Prostate Cancer Risk Locus 3) Development of Kinase Inhibitor Combination Therapy in Prostate Cancer 4) Modulating Transcription Factor Targets via Chemical Genomics 5) Androgen Signaling in Hormone Refractory Disease. These projects will be supported by three cores 1) Administration, evaluation and planning 2) Biostatistics and Computational Biology 3) Tissue and Pathology. We also include Developmental Projects and Career Development Programs. The overall goal of the DF/HCC SPORE is the translation of biological and technological advances into clinically meaningful advances for men with prostate cancer.